Establishment of gastric cancer organoid and its application in individualized therapy

Miao,Xin; Wang,Caiming; Chai,Changpeng; Tang,Huan; Hu,Jinjing; Zhao,Zhenjie; Luo,Wei; Zhang,Hui; Zhu,Kexiang; Zhou,Wence; Xu,Hao

doi:10.3892/ol.2022.13567

Establishment of gastric cancer organoid and its application in individualized therapy

Authors:
- Xin Miao
- Caiming Wang
- Changpeng Chai
- Huan Tang
- Jinjing Hu
- Zhenjie Zhao
- Wei Luo
- Hui Zhang
- Kexiang Zhu
- Wence Zhou
- Hao Xu
View Affiliations

Affiliations: State Key Laboratory of Veterinary Etiological Biology and Office International des Epizooties/National Foot and Mouth Disease Reference Laboratory and Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730000, P.R. China, Department of Tumour and Anorectal, Second People's Hospital of Baiyin City, Baiyin, Gansu 730900, P.R. China, The Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, The First Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: October 26, 2022 https://doi.org/10.3892/ol.2022.13567
Article Number: 447
Copyright: © Miao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The application of cancer organoids is of great value in individualized therapy as an embodiment of the tumor of a patient, a gastric cancer organoid model was established and its application in individualized drug screening was explored. The primary tumor tissues of 3 patients with gastric cancer who underwent primary surgery at the Fourth Department of General Surgery of the First Hospital of Lanzhou University (Lanzhou, China) between July and August 2021 were selected and digested with mixed enzymes to prepare cell suspensions. Of these, two were cultured by mixing with Matrigel, while the cells from the third patient were placed in a 24‑well ultra‑low adhesion plate for suspension organoid culture. After intensive organoid growth, they were digested, passaged, cryopreserved and thawed for further analyses. The formation of gastric cancer organoids was observed under an inverted microscope. One case was selected, and organoids were compared with the original tumor tissue via H&E and immunohistochemical staining to evaluate the consistency of the two. Finally, paclitaxel, oxaliplatin and fluorouracil were administered to the organoids to verify the value of screening individualized drugs. It was indicated that the passage and cryopreservation of gastric cancer organoids were successfully established in all three cases. The H&E and immunohistochemical staining results suggested that the structure and protein expression of the organoids were highly similar to those of the source tumor tissue. The use of established gastric cancer organoids for individualized chemotherapy drug screening is of high clinical value. Gastric cancer organoids with high similarity to the original tissue may be successfully constructed by the suspension growth culture method. The established organoids may serve as an effective model for individualized drug screening.

View Figures

View References

1	Steele NG, Chakrabarti J, Wang J, Biesiada J, Holokai L, Chang J, Nowacki LM, Hawkins J, Mahe M, Sundaram N, et al: An organoid-based preclinical model of human gastric cancer. Cell Mol Gastroenterol Hepatol. 7:161–184. 2019. View Article : Google Scholar : PubMed/NCBI
2	Malvezzi M, Bonifazi M, Bertuccio P, Levi F, La Vecchia C, Decarli A and Negri E: An age-period-cohort analysis of gastric cancer mortality from 1950 to 2007 in Europe. Ann Epidemiol. 20:898–905. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ahmad SA, Xia BT, Bailey CE, Abbott DE, Helmink BA, Daly MC, Thota R, Schlegal C, Winer LK, Ahmad SA, et al: An update on gastric cancer. Curr Probl Surg. 53:449–490. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gunturu KS, Woo Y, Beaubier N, Remotti HE and Saif MW: Gastric cancer and trastuzumab: First biologic therapy in gastric cancer. Ther Adv Med Oncol. 5:143–151. 2013. View Article : Google Scholar : PubMed/NCBI
7	Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M and Ochiai A: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71. 2006.PubMed/NCBI
8	Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH and Scapulatempo-Neto C: HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol. 19:6438–6446. 2013. View Article : Google Scholar : PubMed/NCBI
9	Manion E, Hornick JL, Lester SC and Brock JE: A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol. 135:845–851. 2011. View Article : Google Scholar : PubMed/NCBI
10	Domcke S, Sinha R, Levine DA, Sander C and Schultz N: Evaluating cell lines as tumour models by comparison of genomic profifiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
11	Ertel A, Verghese A, Byers SW, Ochs M and Tozeren A: Pathway-specifific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer. 5:552006. View Article : Google Scholar : PubMed/NCBI
12	Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al: Redefifining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sandberg R and Ernberg I: Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci USA. 102:2052–2057. 2005. View Article : Google Scholar : PubMed/NCBI
14	Stein WD, Bates SE and Fojo T: Intractable cancers: The many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets. 5:333–346. 2004. View Article : Google Scholar : PubMed/NCBI
15	Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, et al: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 359:920–926. 2018. View Article : Google Scholar : PubMed/NCBI
16	Seidlitz T, Koo BK and Stange DE: Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine. Cell Death Differ. 28:68–83. 2021. View Article : Google Scholar : PubMed/NCBI
17	Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, et al: Human gastric cancer modelling using organoids. Gut. 68:207–217. 2019. View Article : Google Scholar : PubMed/NCBI
18	Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, Matano M, Seino T, Nishikori S, Ishikawa K, et al: Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. Cell. 174:856–869.e17. 2018. View Article : Google Scholar : PubMed/NCBI
19	Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, et al: A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 23:882–897.e11. 2018. View Article : Google Scholar : PubMed/NCBI
20	Peraldo-Neia C, Massa A, Vita F, Basiricò M, Raggi C, Bernabei P, Ostano P, Casorzo L, Panero M, Leone F, et al: A novel multidrug-resistant cell line from an Italian intrahepatic cholangiocarcinoma patient. Cancers (Basel). 13:20512021. View Article : Google Scholar : PubMed/NCBI
21	Varamo C, Peraldo-Neia C, Ostano P, Basiricò M, Raggi C, Bernabei P, Venesio T, Berrino E, Aglietta M, Leone F and Cavalloni G: Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line resistant to gemcitabine. Cancers (Basel). 11:5192019. View Article : Google Scholar : PubMed/NCBI
22	Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, et al: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 39:102019. View Article : Google Scholar : PubMed/NCBI
23	Hunt RH, Camilleri M, Crowe SE, El-Omar EM, Fox JG, Kuipers EJ, Malfertheiner P, McColl KE, Pritchard DM, Rugge M, et al: The stomach in health and disease. Gut. 64:1650–1668. 2015. View Article : Google Scholar : PubMed/NCBI
24	Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, et al: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708. 2016. View Article : Google Scholar : PubMed/NCBI
25	Seidlitz T and Stange DE: Gastrointestinal cancer organoids-applications in basic and translational cancer research. Exp Mol Med. 53:1459–1470. 2021. View Article : Google Scholar : PubMed/NCBI
26	Lau HCH, Kranenburg O, Xiao H and Yu J: Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 17:203–222. 2020. View Article : Google Scholar : PubMed/NCBI
27	Xu H, Jiao D, Liu A and Wu K: Tumor organoids: Applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 15:582022. View Article : Google Scholar : PubMed/NCBI
28	Günther C, Winner B, Neurath MF and Stappenbeck TS: Organoids in gastrointestinal diseases: From experimental models to clinical translation. Gut. 71:1892–1908. 2022. View Article : Google Scholar : PubMed/NCBI
29	Sun L, Wang Y, Cen J, Ma X, Cui L, Qiu Z, Zhang Z, Li H, Yang RZ, Wang C, et al: Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 21:1015–1026. 2019. View Article : Google Scholar : PubMed/NCBI
30	Stroulios G, Stahl M, Elstone F, Chang W, Louis S, Eaves A, Simmini S and Conder RK: Culture Methods to Study Apical-Specific Interactions using Intestinal Organoid Models. J Vis Exp. 23((169))2021.PubMed/NCBI
31	Peng J, Xu H and Cai J: Establishment and characterization of a new gastric cancer cell line, XGC-1. Cancer Cell Int. 20:4372020. View Article : Google Scholar : PubMed/NCBI
32	Xu H, Peng JG, Zhuang YF, Chen JJ, Luo QC, Huang WF, Lin CD and Cai JC: Establishment and characterization of an expanding-type gastric cancer cell line by Ming's classification. Oncol Rep. 36:3030–3036. 2016. View Article : Google Scholar : PubMed/NCBI
33	Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, et al: Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8:1112–1129. 2018. View Article : Google Scholar : PubMed/NCBI
34	Li G, Ma S, Wu Q, Kong D, Yang Z, Gu Z, Feng L, Zhang K, Cheng S, Tian Y, et al: Establishment of gastric signet ring cell carcinoma organoid for the therapeutic drug testing. Cell Death Discov. 8:62022. View Article : Google Scholar : PubMed/NCBI